Optogenetics refers to a scientific approach that includes a combination of genetics and optics technologies. It is primarily used for controlling and monitoring the biological functions of neurons and other types of cells with light sensors. This information provides insights into individual behavior and physiology, including movement, learning, memory, navigation, metabolism, respiration, and sensor processing. Optogenetics aids in clinical discoveries by shedding light on the cellular activities associated with various diseases, such as chronic pain, epilepsy, Parkinson disease, stroke, drug addiction, obsessive compulsion disorder (OCD), social dysfunction, and anxiety and depression. On account of these applications, optogenetics finds extensive utilization in the field of neurosciences.
The global optogenetics market reached a value of US$ 31.5 Billion in 2021. Looking forward, IMARC Group expects the market to reach a value of US$ 85.4 Billion by 2027 exhibiting a CAGR of 17.30% during 2022-2027.
The increasing prevalence of neurological disorders due to various infections, ailments, genetic disorders, congenital abnormalities, and brain, nerve, and spinal cord injuries is one of the key factors currently driving the optogenetics market growth. In line with this, the introduction of fiber-coupled light-emitting diode (LED) for being incorporated into the implants to enable the untethered light delivery is acting as another major growth-inducing factor.
Additionally, rapid technological advancements in neural connectivity, wireless microchip, sensors, cell phenotyping tools, and various imaging tools, like computed tomography (CT), position emission tomography (PET), and magnetic resonance imaging (MRI) to precisely evaluate organs and tissues for identifying disorders is propelling the market growth. The rising inclination of healthcare professionals toward optogenetic therapeutic methodologies on account of its cellular, spatial, and temporal precision is further contributing to the market growth. Other factors, including increasing healthcare expenditure, extensive research and development (R&D) activities in the field of neurosciences, and strategic collaborations between key players, pharmaceutical companies, and governments of various nations to implement favorable policies that support the launch of novel drugs for treating neurological diseases, are creating a positive outlook for the market.